Manhattan |
Broadway |
|
| 14:00 – 14:30 | Opening session | |
|---|---|---|
| 14:30 – 16:00 |
Update in cancer-associated thrombosis (CAT) Extracellular vesicles in CAT pathogenesis NOACs or LMWH for cancer-associated VTE Assessment of bleeding risk Tailoring anticoagulation beyond six months |
Emerging technologies and thrombosis Artificial intelligence in managing thrombosis Nanoparticles in thrombosis research Modulating Lp(a) to reduce thrombus burden? Circulating miRNAs in the pathophysiology of atherosclerosis and thrombosis |
| 16:00 – 16:30 | Coffee and poster exhibition | |
| 16:30 – 17:30 |
Dilemmas in antithrombotic treatment in CAD Is there a place for P2Y12 pre-treatment in STEMI? Antithrombotic treatment beyond the first year of ACS Hypofibrinolysis in CAD: how to tailor management? |
Thrombosis, immunity and inflammation DIC a thrombotic microangiopathy in sepsis and COVID-19 Von Willebrand Factor and inflammation: a new key role beyond haemostasis From basic science to therapeutics of platelet GP VI |
| 17:30 – 18:30 |
Laboratory measurements of platelet function and NOACs Monitoring platelet function: is it worth it? Functional assays in the diagnosis of Heparin-Induced Thrombocytopenia Laboratory testing in patients treated with NOACs |
What the clinicians should know about COVID-19 Soluble biomarkers of thrombosis in COVID-19 The interplay between inflammation and thrombosis in COVID-19 Vaccines: where we are ? |
Morning sessions
Manhattan |
Broadway |
|
| 08:30 – 10:00 | Moderated posters | Case based session |
|---|---|---|
| 10:00 – 11:00 |
Managing antithrombotic therapy in challenging scenarios Anticoagulation in mesenteric thrombosis Indications for endovascular management in VT Patients with cancer at risk of thrombocytopenia |
New concepts, new options, new targets for treatment Novel antiplatelet agents in ischemic CV disease Factors XI and XII as targets for new anticoagulants. Factor XI in arterial vascular disease |
| 11:00 – 11:30 | Coffee and poster exhibition | |
| 11:30 -13:00 |
The different faces of thrombosis Thrombosis in Hemoglobinopathies Cancer-associated pulmonary embolism Antineoplastic treatment modalities: Effects on coagulation Antiphospholipid syndrome |
Thrombotic diseases in the paediatric age Thrombosis in neonates, children, adolescents and young adults NOAC and DVT in children- are we there? Thrombophilia causing in utero thrombosis: what´s new? Anticoagulant treatment of paediatric cancer patients |
| 13:00 – 14:00 | Satellite Symposium Sponsored by  |
Satellite symposium / sponsored session |
Afternoon sessions
Manhattan |
Broadway |
|
| 14:00 – 14:30 | Main Lecture «JOSÉ ANTONIO IRIARTE» | Main lecture Personalized medicine in thrombosis |
|---|---|---|
| 14:30 – 16:00 |
Inherited thrombophilias Thrombophilia testing in daily practice: who and when? Genetics as a powerful tool in prediction of VT Paediatric Thrombophilia Update in clinical guidelines for thrombophilia testing |
The fine balance between thrombosis and bleeding Pregnancy and need for anticoagulation Current place for monitoring NOACs Reversal agents, new developments Anticoagulation and bleeding in ECMO |
| 16:00 – 16:30 | Coffee and poster exhibition | |
| 16:30 – 17:30 |
Practical session: how to do it How long should we treat children with DVT? Aspirin in the primary prevention setting |
Tips and tricks for the young investigator The perspective of a basic scientist The perspective of a clinician |
| 17:30 – 18:30 | Satellite symposium /sponsored session | Satellite symposium /sponsored session |
| 18.30 | EMLTD General Assembly | |
Morning sessions
Manhattan |
Broadway |
|
| 08:30 – 10:00 | Oral presentations | Oral presentations |
|---|---|---|
| 10:00 – 11:00 |
Meet the scientist Two scientists (one basic, one clinician) will share with the audience their plans and lines for research |
Core Curriculum Session Deep vein thrombosis and pulmonary embolism Insights in aetiology, pathogenesis and prognosis of VT Biomarkers for predicting venous thrombosis Gestational vascular complications |
| 11:00 – 11:30 | Coffee and poster exhibition | |
| 11:30 – 13:00 |
Systemic thrombosis, old and new players Thrombotic microngiopathies Von Willebrandt factor in inflammatory thrombosis Obesity, diabetes and arterial thrombosis Plaque erosion: different thrombogenicity? |
Stroke, a continuous matter for debate Factor XI a new target for antithrombotic therapy GP VI targeting in ischemic stroke Left atrial appendage closure for stroke prevention Lytics, why, when, for whom |
| 13:00 – 14:00 | Satellite symposium /sponsored session | Satellite symposium /sponsored session |
Afternoon sessions
Manhattan |
Broadway |
|
| 14:00 – 14:30 | Main lecture «MICHEL SAMAMA” Thrombosis in women: gender differences |
Main Lecture Nutrition, Mediterranean diet and atherothrombosis |
|---|---|---|
| 14:30 – 16:00 |
Core Curriculum Session Bleeding «the dark side of the moon» Thrombotic microngiopathies Monotherapy after acute coronary syndromes. Less is more? Thrombosis and bleeding in liver disease Factor XI inhibition. A big promise Bleeding Risk Assessment in end-stage kidney disease |
Managing antithrombotic therapy in challenging scenarios Mechanical valve prosthesis and major bleeding Transcatheter valve replacement in the very old population Thrombosis and bleeding in liver disease Atrial fibrillation and high-risk or spontaneous intracranial bleeding Invasive procedures in patients with high bleeding risk |
| 16.00 | Closing session and awards |